共 50 条
[21]
Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
[J].
Applied Health Economics and Health Policy,
2021, 19
:371-387
[25]
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
[J].
Cost Effectiveness and Resource Allocation,
15
[28]
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
[J].
Advances in Therapy,
2015, 32
:1117-1127